Israel was solving the chemistry of cannabis in the 1960s while the rest of the world was still calling it dope. The country has the oldest national medical cannabis program (since 1992), the highest per-capita medical patient rate of any tracked country, and more cannabis pharmaceutical research per capita than anywhere else. The only Middle Eastern country with legal medical access. The IDF tests cannabis for PTSD in veterans.
A personal note from the owner: my parents are Israeli, and most of my family is still there. Israel's cannabis story has always mattered to me. The science came out of Israeli universities. The medical model was built decades before anyone else tried. This page is the version I would have wanted to read when I was first looking into it.
The reason every legal cannabis market on earth has a chemical framework to talk about is that Israeli researchers built it. If you have read about THC, CBD, anandamide, or the endocannabinoid system, you are reading downstream from work that started in Jerusalem.
Israeli organic chemist who isolated and identified the structure of THC in 1964 at Hebrew University in Jerusalem. He went on to identify CBD's structure, characterize the endocannabinoid system, and discover anandamide (the brain's own cannabinoid). No single scientist contributed more to cannabis pharmacology. He published into his 90s and died in 2023, still working.
Israeli physicians like Cohen helped build the world's first national medical cannabis framework starting in 1992. Israel's Ministry of Health began authorizing physicians to prescribe cannabis for specific conditions decades before any US state, much less the federal government, considered it.
Israel's first medical cannabis cultivator, named for the Hebrew phrase meaning 'repair of the world.' Pioneered strain-specific clinical research, developed the high-CBD Avidekel cultivar (an early dedicated CBD strain), and supplied a meaningful share of Israeli patients for over a decade before the international cannabis industry caught up.
Israel does not have a recreational cannabis market in the way the United States or Canada does. What it has is a national medical cannabis program that started in 1992 under the Ministry of Health, scaled through the 2000s and 2010s, and as of recent counts had over 100,000 registered patients. Per capita, that is a higher participation rate than any US state.
A physician licensed by the Ministry of Health (Yakar) writes a prescription. The patient receives a permit listing approved cultivars and dosing. Until 2019, supply came directly from a small list of approved cultivators. After 2019, the system reformed toward a pharmacy distribution model: patients pick up at participating pharmacies, the cultivators sell to wholesalers, and the prescription is filled like any other regulated medication.
The approved indications are broader than in most American medical programs. PTSD, fibromyalgia, chronic pain, cancer side effects, epilepsy, Crohn's and IBD, multiple sclerosis spasticity, and specific pediatric conditions are all explicitly covered. The framework was built to be evidence-driven rather than condition-by-condition political. That is the legacy of starting with researchers rather than activists.
Most of Israel's cannabis companies are clustered around the Tel Aviv tech corridor (Tel Aviv-Yokneam-Rehovot). Several are publicly traded on Nasdaq, TASE, or the Toronto Stock Exchange. The country exports more cannabis research IP than it exports cannabis itself.
Medical cultivator and IP licensor; the originator of strain-specific medical cannabis research.
Israel's largest medical cannabis producer. Public on Nasdaq + TASE. Operates the Canndoc brand.
Israeli-Canadian company with operations in Israel and Germany. Public on Nasdaq + TSX.
Pharmaceutical-grade cannabis development. Clinical trials for specific indications.
Cancer-focused cannabis research. Develops personalized cannabinoid therapy.
Cannabis pharmaceutical R&D, focused on standardized dose-form delivery (sublinguals, suppositories).
Israel has one of the highest per-capita military service rates in the world. Most Israelis serve two to three years, many in combat or combat-support roles. The country has lived through major wars and decades of asymmetric conflict. The PTSD burden on the population is substantial, and well-acknowledged.
The Israeli military medical corps (IDF Medical Corps) began studying cannabis for veteran PTSD treatment in the 2010s, well before similar US Department of Veterans Affairs studies got serious traction. Israeli veterans with documented PTSD became one of the largest single demographics in the medical cannabis program. The research output from those trials has shaped how cannabis is studied for trauma globally.
Note the inversion here. In the US, cannabis-for-PTSD research faced political obstacles for decades because cannabis was federal Schedule I. In Israel, it was a straightforward research question handled by the military medical apparatus directly.
Recreational cannabis remains technically illegal in Israel. But possession of small amounts for personal use was decriminalized in 2017, with first offenses now drawing fines rather than arrest. Practical enforcement varies dramatically by location. In Tel Aviv, recreational use is functionally a non-issue. In more religious or politically conservative areas, enforcement is more active.
Successive coalition governments have debated full legalization without passing it. The political math is hard. The cannabis community has consistent support, but cannabis legalization is often tied into broader coalition negotiations that prevent any single bill from clearing.
The result is a country that is one of the most permissive in the world for medical cannabis and one of the slowest in the developed world for recreational legalization, all at once.
The cannabinoid science Mechoulam started in Jerusalem powers the modern medical conversation worldwide. The way Israel built its medical program is the model many US states are catching up to.